GLP-1 drugs and PCOS insulin resistance: separating signal from hype

What did @haleighweaver5 actually say?

She stopped Zepbound (tirzepatide) for about a month after breast surgery, gained roughly eight pounds, then lost it within two weeks of restarting. Her main advice: don't quit cold turkey. "If you go off at the right way you will not have any issues," she says, recommending a slow taper instead of stopping abruptly. She also attributes much of the weight gain to surgical inflammation and water retention, not true fat regain. She frames the experience as evidence that GLP-1 users shouldn't fear stopping the medication.

This is a personal anecdote, not a clinical recommendation, and she's clear about that framing. But 92,000 viewers are going to draw clinical conclusions from it anyway, so the claims deserve a harder look.

Does the science back this up?

Partially. The weight regain data after stopping GLP-1 receptor agonists is real and well-documented, but her one-month experience is unusually mild compared to what controlled trials show. The STEP 4 trial (Rubino et al., 2021, NEJM) found that participants who stopped semaglutide regained two-thirds of their lost weight within one year. A tirzepatide withdrawal study from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed participants regained about half their lost weight after stopping, compared to continued treatment.

Her eight-pound gain over one month, largely attributed to inflammation and fluid retention after surgery, is plausible. Surgical stress raises cortisol, increases fluid retention, and disrupts appetite regulation. That part has biological logic behind it. But framing a one-month post-surgical pause as representative of what most people experience when stopping GLP-1 therapy is not accurate, and that's the part that needs correcting.

What did they get wrong (or right)?

She got the inflammation and water retention explanation largely right. Post-surgical fluid shifts and cortisol spikes can absolutely cause transient weight gain that resolves without fat accumulation. That's not quackery, that's physiology.

Where she goes wrong is the taper advice. She says to "slowly go down and take yourself off" to avoid reverting to old habits. There is no strong clinical evidence that tapering a GLP-1 agonist meaningfully reduces rebound weight gain. The SURMOUNT-4 and STEP 4 data tracked abrupt discontinuation, but no large trial has compared tapered versus abrupt stopping on long-term weight outcomes. The taper logic she uses, comparing it to quitting anything cold turkey, is borrowed loosely from addiction medicine and doesn't map cleanly onto GLP-1 pharmacology.

She also says "you will not have any issues" if you go off correctly. That's overconfident. For people with PCOS and insulin resistance, specifically the population her hashtags are targeting, stopping GLP-1 therapy can trigger significant metabolic regression. Her surgical context was unusual and temporary.

What should you actually know?

The weight regain after stopping GLP-1 medications is a documented pattern, not a character flaw or a failure. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) is the clearest tirzepatide-specific evidence: after 36 weeks of stopping, participants who switched to placebo regained approximately 14 percentage points of body weight compared to those who continued. That's substantial.

For people using GLP-1 therapy specifically for PCOS-related insulin resistance, the stakes of stopping are different than for someone without an underlying metabolic condition. Insulin sensitivity improvements may reverse when the drug clears. A one-month pause post-surgery in an otherwise healthy protocol is very different from a full discontinuation.

If you are considering stopping tirzepatide or semaglutide for any reason, that conversation needs to happen with a licensed prescriber who knows your full metabolic picture, not from a TikTok comment section. Her experience is one data point. The clinical literature is a much larger one.